Oxaliplatin (Eloxatin) will now be available in a new 200-mg single-use vial.
Oxaliplatin (Eloxatin) will now be available in a new 200-mg single-use vial and, according to the manufacturer Sanofi-Aventis, will provide more convenience to pharmacists and nurses preparing the product for patients with body surface areas greater than 1.76 m2 who require at least 150-mg dosage of the drug. Oxaliplatin is indicated for use in combination with 5-fluorouracil and leucovorin for the adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor and for advanced carcinoma of the colon or rectum. Previously, 50- and 100-mg vials were available. The new 200-mg vial will be available nationwide beginning this week.